These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 28791634)

  • 21. Neratinib, A Novel HER2-Targeted Tyrosine Kinase Inhibitor.
    Tiwari SR; Mishra P; Abraham J
    Clin Breast Cancer; 2016 Oct; 16(5):344-348. PubMed ID: 27405796
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of a multiplexed immunoassay (PRO Onc assay) to detect HER2 abnormalities in circulating tumor cells of women with HER2-negative metastatic breast cancer: lack of response to HER2-targeted therapy.
    Hainsworth JD; Murphy PB; Alemar JR; Daniel BR; Young RR; Yardley DA
    Breast Cancer Res Treat; 2016 Nov; 160(1):41-49. PubMed ID: 27632289
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A review of HER2-targeted therapy in breast and ovarian cancer: lessons from antiquity - CLEOPATRA and PENELOPE.
    Hodeib M; Serna-Gallegos T; Tewari KS
    Future Oncol; 2015; 11(23):3113-31. PubMed ID: 26597460
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biological considerations and clinical applications of new HER2-targeted agents.
    Higa GM; Singh V; Abraham J
    Expert Rev Anticancer Ther; 2010 Sep; 10(9):1497-509. PubMed ID: 20836684
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bevacizumab as first-line treatment in HER2-negative advanced breast cancer: pros and cons.
    Sini V; Cassano A; Corsi D; De Laurentiis M; Gamucci T; Mauri M; Naso G; Roselli M; Ruggeri EM; Tonini G; Vici P; Zampa G; Marchetti P
    Tumori; 2016 Oct; 102(5):472-480. PubMed ID: 27647231
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dual human epidermal growth factor receptor 2 blockade: another step forward in treating patients with human epidermal growth factor receptor 2-positive breast cancer.
    Zardavas D; Bozovic-Spasojevic I; de Azambuja E
    Curr Opin Oncol; 2012 Nov; 24(6):612-22. PubMed ID: 23014186
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Optimizing outcomes in HER2-positive breast cancer: the molecular rationale.
    Esteva FJ; Pusztai L
    Oncology (Williston Park); 2005 Nov; 19(13 Suppl 5):5-16. PubMed ID: 19364051
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Recent advances in targeted therapies in the treatment of HER2-positive metastatic breast cancer].
    Ismaili N; Belbaraka R; Elomrani A; Khouchani M; Tahri A
    Presse Med; 2013 Nov; 42(11):1461-8. PubMed ID: 23721860
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neoadjuvant neratinib promotes ferroptosis and inhibits brain metastasis in a novel syngeneic model of spontaneous HER2
    Nagpal A; Redvers RP; Ling X; Ayton S; Fuentes M; Tavancheh E; Diala I; Lalani A; Loi S; David S; Anderson RL; Smith Y; Merino D; Denoyer D; Pouliot N
    Breast Cancer Res; 2019 Aug; 21(1):94. PubMed ID: 31409375
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapeutic approach to the management of HER2-positive breast cancer metastatic to the brain.
    Patil A; Sherbet GV
    Cancer Lett; 2015 Mar; 358(2):93-99. PubMed ID: 25529010
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The evolving understanding of small HER2-positive breast cancers: matching management to outcomes.
    Waks AG; Tolaney SM
    Future Oncol; 2015; 11(24):3261-71. PubMed ID: 26634944
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Evolving Landscape of HER2 Targeting in Breast Cancer.
    Moasser MM; Krop IE
    JAMA Oncol; 2015 Nov; 1(8):1154-61. PubMed ID: 26204261
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of HER2-targeted therapy in metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors.
    Nielsen DL; Kümler I; Palshof JA; Andersson M
    Breast; 2013 Feb; 22(1):1-12. PubMed ID: 23084121
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Advances in targeting HER2-positive breast cancer.
    Harbeck N
    Curr Opin Obstet Gynecol; 2018 Feb; 30(1):55-59. PubMed ID: 29194077
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting the HER2 receptor in metastatic breast cancer.
    Orphanos G; Kountourakis P
    Hematol Oncol Stem Cell Ther; 2012; 5(3):127-37. PubMed ID: 23095788
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Patients with anti-HER2 responsive disease: definition and adjuvant therapies.
    Burstein HJ
    Breast; 2011 Oct; 20 Suppl 3():S132-4. PubMed ID: 22015280
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeted Therapy for Premenopausal Women with HR
    Bardia A; Hurvitz S
    Clin Cancer Res; 2018 Nov; 24(21):5206-5218. PubMed ID: 29884743
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Emerging treatment options for the management of brain metastases in patients with HER2-positive metastatic breast cancer.
    Chien AJ; Rugo HS
    Breast Cancer Res Treat; 2013 Jan; 137(1):1-12. PubMed ID: 23143215
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Management of patients with HER2-positive metastatic breast cancer: is there an optimal sequence of HER2-directed approaches?
    Zelnak AB; Wisinski KB
    Cancer; 2015 Jan; 121(1):17-24. PubMed ID: 25056442
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Drug Insight: intracellular inhibitors of HER2--clinical development of lapatinib in breast cancer.
    Cameron DA; Stein S
    Nat Clin Pract Oncol; 2008 Sep; 5(9):512-20. PubMed ID: 18594499
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.